Aura secured an additional $8 million round of funding to advance AU-011 to the clinic. The company also announced the addition of Henri Termeer, former CEO of Genzyme and major Aura investor, to its Board of Directors, and welcomed key new Clinical Advisory Board (CAB) members, all distinguished ocular oncologists.
Aura's CEO, Eli de los Pinos, will present a company overview at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2016 Annual Meeting (OIS@AAO) in Chicago on Thursday, October 13, 2016, at 11 a.m. EST.
We are Developing a New Class of Therapies to Target and Destroy Cancer Cells Selectively
Current treatments for cancers like ocular melanoma are highly invasive and often imprecise and toxic. We are creating a new class of therapies that can pinpoint solid tumors and metastases without harming surrounding tissue, enabling targeted treatment across a wide range of cancers.